NO20011491L - Reduksjon av oksidative stress faktorer - Google Patents

Reduksjon av oksidative stress faktorer

Info

Publication number
NO20011491L
NO20011491L NO20011491A NO20011491A NO20011491L NO 20011491 L NO20011491 L NO 20011491L NO 20011491 A NO20011491 A NO 20011491A NO 20011491 A NO20011491 A NO 20011491A NO 20011491 L NO20011491 L NO 20011491L
Authority
NO
Norway
Prior art keywords
oxidative stress
stress factors
reduction
propionibacterium
ros
Prior art date
Application number
NO20011491A
Other languages
English (en)
Other versions
NO20011491D0 (no
Inventor
Marek Naruszewicz
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9803334A external-priority patent/SE9803334L/xx
Priority claimed from SE9900371A external-priority patent/SE9900371D0/xx
Application filed by Probi Ab filed Critical Probi Ab
Publication of NO20011491L publication Critical patent/NO20011491L/no
Publication of NO20011491D0 publication Critical patent/NO20011491D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Oppfinnelsen er rettet mot anvendelse av en bakteriestamme, fortrinnsvis fra slekten Lactobacillus eller Propionibacterium, som fører til økede mengder av propionsyre i tarmene for fremstilling av et medikament for reduksjon av nivået av oksidative stressfaktorer, slik som EL-6, reaktive oksygen forbindelser (ROS), og adhesjonsmolekyler i pattedyr inkludert menneske. Medikamentet kan bli anvendt for profylakse og/eller behandling av kroniske inflammatoriske sykdommer slik som reumatiske sykdommer og psoriasis.
NO20011491A 1998-10-01 2001-03-23 Reduksjon av oksidative stress faktorer NO20011491D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803334A SE9803334L (sv) 1998-10-01 1998-10-01 Reduktion av ROS
SE9900371A SE9900371D0 (sv) 1999-02-04 1999-02-04 New use
PCT/SE1999/001741 WO2000020013A1 (en) 1998-10-01 1999-10-01 Reduction of oxidative stress factors

Publications (2)

Publication Number Publication Date
NO20011491L true NO20011491L (no) 2001-03-23
NO20011491D0 NO20011491D0 (no) 2001-03-23

Family

ID=26663406

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011491A NO20011491D0 (no) 1998-10-01 2001-03-23 Reduksjon av oksidative stress faktorer

Country Status (11)

Country Link
US (2) US6830750B1 (no)
EP (1) EP1117414A1 (no)
JP (1) JP2002526413A (no)
KR (1) KR20010075495A (no)
CN (1) CN1188140C (no)
AU (1) AU764011B2 (no)
BR (1) BR9914184A (no)
CA (1) CA2345110A1 (no)
NO (1) NO20011491D0 (no)
PL (1) PL347029A1 (no)
WO (1) WO2000020013A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796555B1 (fr) * 1999-07-20 2003-12-19 Standa Lab Sa Utilisation de bacteries propioniques pour la production d'acide propionique et/ou de propionates et, le cas echeant, d'acide acetique et/ou d'acetates au niveau du colon
EP1374878A1 (en) * 2002-06-20 2004-01-02 N.V. Nutricia Method and composition for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract
JP4521687B2 (ja) 2002-06-21 2010-08-11 ニューキャッスル イノベーション リミテッド プロバイオティクス、プロピオニバクテリウム・イエンセニー７０２
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
US7820382B2 (en) 2004-08-03 2010-10-26 Bauer A Robert Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation
US8080373B2 (en) * 2004-08-03 2011-12-20 Bauer Jr A Robert Method for the early detection of pancreatic cancer and other gastrointestinal disease conditions
CA2579709A1 (en) * 2004-09-10 2006-03-16 Kirin Beer Kabushiki Kaisha Method for stabilizing the antiallergic activity of lactic acid bacteria aganst high-temperature treatment, stabilized compositions, and food and drink
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
US8420376B2 (en) * 2005-10-06 2013-04-16 Probi Ab Use of Lactobacillus for treatment of virus infections
WO2009018447A2 (en) * 2007-07-31 2009-02-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
TW201106957A (en) * 2009-08-31 2011-03-01 Synbio Tech Inc The new strain of Lactobacillus plantarum LP28 and its use in treating allergy
BR112012016861A2 (pt) 2010-01-08 2017-09-26 Biopolis SL "método para seleção de bactéria com ação antioxidante".
PL2521769T3 (pl) 2010-01-08 2017-01-31 Gervais Danone Sa Pałeczki kwasu mlekowego z działaniem przeciwutleniającym
WO2012014971A1 (ja) * 2010-07-30 2012-02-02 株式会社明治 メタボリックシンドローム改善効果を有する乳酸菌
EE05750B1 (et) * 2011-02-25 2015-06-15 OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tüvi Lactobacillus gasseri MCC2 DSM 23882 ning selle kasutamine
GB201600975D0 (en) * 2016-01-19 2016-03-02 Probi Ab Novel strain of probiotic bacteria and compositions and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102419A (en) * 1976-02-23 1977-08-27 Seikenkai Lactic acid producing bacillus preparation
JP3510639B2 (ja) * 1991-06-28 2004-03-29 カルピス株式会社 インターロイキン産生能を調節する機能を持たせた機能性食品又は健康食品
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
EP0649603B1 (en) 1993-05-11 2000-10-25 Otsuka Pharmaceutical Co., Ltd. Antioxidant food, antioxidant preparation and antioxidization method
SE9501056D0 (sv) * 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
IT1288119B1 (it) * 1996-06-28 1998-09-10 Renata Maria Anna Ve Cavaliere Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
SE510753C2 (sv) 1997-08-05 1999-06-21 Probi Ab Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use

Also Published As

Publication number Publication date
WO2000020013A1 (en) 2000-04-13
US20050084484A1 (en) 2005-04-21
AU1088700A (en) 2000-04-26
CN1188140C (zh) 2005-02-09
BR9914184A (pt) 2001-06-19
CN1320039A (zh) 2001-10-31
EP1117414A1 (en) 2001-07-25
AU764011B2 (en) 2003-08-07
CA2345110A1 (en) 2000-04-13
NO20011491D0 (no) 2001-03-23
KR20010075495A (ko) 2001-08-09
PL347029A1 (en) 2002-03-11
JP2002526413A (ja) 2002-08-20
US6830750B1 (en) 2004-12-14

Similar Documents

Publication Publication Date Title
NO20011491L (no) Reduksjon av oksidative stress faktorer
Golub et al. Periodontal therapeutics: Current host‐modulation agents and future directions
Das “Cell membrane theory of senescence” and the role of bioactive lipids in aging, and aging associated diseases and their therapeutic implications
Tiwari The role of serratiopeptidase in the resolution of inflammation
Rosenberg et al. Immunometabolic crosstalk during bacterial infection
Zheng et al. Ameliorative effect of Trametes orientalis polysaccharide against immunosuppression and oxidative stress in cyclophosphamide-treated mice
Park et al. Anti-inflammatory effects of short chain fatty acids in IFN-γ-stimulated RAW 264.7 murine macrophage cells: Involvement of NF-κB and ERK signaling pathways
Lew et al. Bioactives from probiotics for dermal health: functions and benefits
Connolly et al. From ingestion to colonization: the influence of the host environment on regulation of the LEE encoded type III secretion system in enterohaemorrhagic Escherichia coli
Shen et al. Integrated stress responses in Salmonella
Jones et al. Evidence-based medicine: wound management
Castro et al. The use of an antioxidant dressing on hard-to-heal wounds: A multicentre, prospective case series
Moodley et al. The relationship between periodontitis and diabetes: a brief review: clinical review
US8211947B2 (en) Composition and method for treating and preventing musculoskeletal and connective tissue disorders
ES2112818T1 (es) Composicion farmaceutica que comprende lactobacillus plantarum y arginina.
Shi et al. A clinic trial evaluating the effects of aloe vera fermentation gel on recurrent aphthous stomatitis
FR2930730B1 (fr) Procede d'obtention d'un extrait de marc de canneberge utilisable notamment dans la prevention et le traitement d'affections telles que caries, gingivites, maux de gorge
Silk et al. Inflammatory bowel disease: nutritional implications and treatment
Giamarellos-Bourboulis et al. In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation
Kia et al. Alterations in mitochondrial and inflammasome homeostasis by 2-chloroethyl ethyl sulfide and their mitigation by curcumin: an in vitro study
AR034920A1 (es) Metodos para el tratamiento de enfermedades intestinales inflamatorias
Adimoolam et al. Lower limb cellulitis in non-diabetic patients: a prospective study
Morimoto-Yamashita et al. A natural therapeutic approach for the treatment of periodontitis by MK615
DiBardino et al. Acute respiratory failure after pleurodesis with doxycycline
Zoheir et al. Study of the therapeutic effects of Lactobacillus and α-lipoic acid against dimethylnitrosamine-induced liver fibrosis in rats

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application